ARTICLE | Company News
Horizon gains first FDA approval in thyroid eye disease
January 21, 2020 11:53 PM UTC
Updated on Jan 25, 2020 at 4:34 AM UTC
With FDA’s approval of Horizon’s thyroid eye disease drug -- the first for the indication -- the company is looking ahead to add to its rare disease pipeline through deal-making.
The approval comes ahead of the March 8 PDUFA date for Tepezza teprotumumab-trbw, continuing the recent trend of speedy FDA approvals (see “FDA Approvals in 2019”)...
BCIQ Company Profiles
BCIQ Target Profiles
Insulin-like growth factor-1 (IGF-1) receptor (IGF1R) (CD221)